PRESS RELEASES

SHEPHERD THERAPEUTICS FOUNDER AND CEO DAVID HYSONG NAMED TO FORBES 30 UNDER 30: HEALTHCARE

Rare Cancer Patient Recognized for Contribution to Healthcare Sector

CAMBRIDGE, MA— January 3, 2017 — Today, SHEPHERD Founder and CEO David Hysong was announced as a member of the Forbes 3o Under 3o Class of 2017.

SHEPHERD THERAPEUTICS APPOINTS CMO, COO, AND STRATEGIC RESEARCH ANALYST

Mission-Driven Biotech Strengthens Resources to Cure Rare Cancers

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced the appointments of Abby Reiner, Elizabeth Hostetter, and Jon Goetz to serve as Chief Marketing and Business Development Officer, Chief Operating Officer, and Strategic Research Analyst, respectively.

SHEPHERD THERAPEUTICS APPOINTS CHIEF RESEARCH OFFICER AND CHIEF CREATIVE OFFICER

Life Sciences Company Expands Team

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced the appointments of Jamie Dempsey Barber, PhD and Lacie Randall to serve as Chief Research Officer and Chief Creative Officer, respectively.

SHEPHERD THERAPEUTICS ANNOUNCES DR. JOHANNE KAPLAN AS CHIEF SCIENTIFIC OFFICER

Biotech Veteran Joins the Mission to Cure Rare Cancer

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced it has appointed Johanne Kaplan, PhD, to the position of Chief Scientific Officer.

SHEPHERD THERAPEUTICS HOSTS NASHVILLE HOLIDAY CONCERT

Local Biopharma Company Supports Local Music Scene

Nashville, TN— November 29, 2016 — Leave it to an eclectic town like Nashville to bring together Grammy-award-winning musicians, a famous boy band member, an entertainment networking group featured in Forbes, and a 29-year-old Harvard entrepreneur who founded his own biotech company to celebrate the holidays.

SHEPHERD THERAPEUTICS TO FOCUS ON RARE CANCER CURES

Rare Cancer Patient Founds Biopharma Company To Treat Fellow Rare Cancer Patients

CAMBRIDGE, MA— November 24, 2016 — David Hysong is fighting for his life and using his story to save the lives of others. After being diagnosed with Adenoid Cystic Carcinoma (ACC), a rare cancer for which there is no cure or approved therapy, David reached out to former Genzyme senior vice president Gene Williams. Together they founded the rare cancer-focused biopharma company, SHEPHERD Therapeutics, on January 1, 2016.